DISTRIBUTION DEAL MADE FOR PROSTATE CANCER DIAGNOSTIC TEST

Signet Laboratories has signed an agreement with AsymmetRx to provide exclusive distribution of its Prostate-63 Prostate Cancer Diagnostic Kit. The kit, jointly developed and exclusively marketed by Signet, is the only FDA-cleared prostate cancer kit of its kind.

"Prostate cancer is one of the most difficult cancers to diagnose from biopsied material, and the p63- based test adds a significant advantage to making a correct diagnosis," said Maria McKeon, AsymmetRx's president and CEO.

"This kit ushers in the only FDA cleared prostate cancer test, which aids pathologists in the differential diagnosis of prostate cancer in conjunction with morphological findings. Numerous articles in top clinical journals have cited the accuracy and utility of p63 for prostate cancer diagnosis," she added.